Targeting a specific protein to treat a type of blood cancer
Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia
This study is looking at a new pill called Onvansertib to see if it can help people with a tough type of blood cancer called chronic myelomonocytic leukemia (CMML) that hasn't responded to other treatments, especially for those with specific gene changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11067766 on NIH RePORTER |
What this research studies
This research focuses on chronic myelomonocytic leukemia (CMML), a serious blood cancer with poor outcomes. It aims to develop targeted therapies for patients with the proliferative subtype of CMML, which often has mutations in the RAS pathway. The study will test a new oral medication called Onvansertib, which inhibits a protein known as PLK1, in patients whose cancer has returned or is resistant to other treatments. By using innovative trial designs, the research seeks to determine the safety and effectiveness of this treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory proliferative chronic myelomonocytic leukemia who have RAS pathway mutations.
Not a fit: Patients with other types of leukemia or those who do not have RAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with relapsed or refractory chronic myelomonocytic leukemia.
How similar studies have performed: Previous studies have shown promise in targeting PLK1 in similar blood cancers, indicating potential for success in this novel approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Patnaik, Mrinal Shiv — Mayo Clinic Rochester
- Study coordinator: Patnaik, Mrinal Shiv
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.